Send to a Friend Share

Wachovia Downgrades Valeant Pharmaceuticals (VRX) to Underperform; Risk/Reward Unfavorable

June 9, 2009 8:00 AM EDT
VRX Hot Sheet
Rating Summary:
    6 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 7 | New: 23
Wachovia downgrades Valeant Pharmaceuticals (NYSE: VRX) to Underperform. Valuation Range: $15 to $17.

Wachovia analyst says, "Three factors for the downgrade: bolt on acquisition strategy is unsustainable, in our opinion, current valuation prices in potential reward for retigabine but not the potential risks, and shares are trading at a significant premium relative to peers...Lowering our 2009 EPS estimate to $1.16 from $1.26 (including amortization). The change reflects the addition of the 8.375% notes, partially offset by 2.5% interest earned on the cash received. We are lowering our 2010 EPS estimate to $1.13 from $1.29 for the same reasons."

To see more analyst ratings on VRX Click Here.

Valeant Pharmaceuticals International is a multi-national specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.

You May Also Be Interested In


Related Categories

Downgrades

Related Entities

Wachovia

Add Your Comment





Follow StreetInsider.com On Twitter